Weight Loss Drug Will Be Offered for $499 a Month for Some Patients – The New York Times

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients  The New York Times

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients – The New York Times

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients  The New York Times

Amgen just got one step closer to bringing its Ozempic competitor to market – Yahoo

Amgen just got one step closer to bringing its Ozempic competitor to market  Yahoo

Good old pills vie for weight-loss market – Chemical & Engineering News

Good old pills vie for weight-loss market  Chemical & Engineering News

This state will provide weight loss medication to Medicaid patients starting in 2026: Will the bill pass? – Marca English

This state will provide weight loss medication to Medicaid patients starting in 2026: Will the bill…

Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound – PBS NewsHour

Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound  PBS NewsHour

Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales – MedCity News

Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales  MedCity News

Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025

Sales in Sandoz’s biosimilar business grew 30% buoyed by US launches including Humira-biosimilar.

Novo Nordisk Joins Legal Battle Over Weight Loss Drug Shortage – Bloomberg Law

Novo Nordisk Joins Legal Battle Over Weight Loss Drug Shortage  Bloomberg Law

Jazz Pharmaceuticals bids for Chimerix in $935m deal

The acquisition will give Jazz access to Chimerix’s lead investigational candidate dordaviprone.